Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Migraine is the third most common illness in the world, with about 14 percent of the global population experiencing migraine ...

Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT. The importance of biosimilars only continues ...

Have top stories from The Daily Pennsylvanian delivered to your inbox every day, Monday through Friday, when Penn classes are in session.